natgillin/translations-raw huggingface dataset:
In methaemoglobinaemia, your blood contains too much methaemoglobin (an abnormal form of haemoglobin that is not able to transport oxygen around your body effectively). 
Kod methemoglobinemije krv sadrži previše methemoglobina (abnormalan oblih hemoglobina koji ne može učinkovito prenositi kisik po Vašem tijelu).
The medicine must be used immediately after opening or dilution. 
Ovaj lijek se mora primijeniti odmah nakon otvaranja ili razrjeđivanja.
Intravenous injection of methylthioninium chloride has occasionally caused hypotension and cardiac arrhythmias, and such disorders might prove fatal on rare occasions. 
Intravenska injekcija metiltioninijeva klorida povremeno je uzrokovala hipotenziju i srčane aritmije, a takvi poremećaji mogu u rijetkim prilikama imati smrtni ishod.
Phototoxicity / Photosensitivity 
Nepoznato fototoksičnost/fotosenzitivnost
You should not be given methylthioninium chloride at the same time you are taking certain medicines to treat depression or anxiety which affect a brain chemical called serotonin. 
Ne biste trebali primiti metiltioninijev klorid ako u isto vrijeme kada uzimate i određene lijekove za liječenje depresije ili tjeskobe koji utječu na kemikaliju u mozgu koja se zove serotonin.
Infants 3 months old or younger 
Djeca od 3 mjeseca starosti i mlađa
• Hypersensitivity to the active substance, or to any other thiazine dyes 
• Preosjetljivost na djelatnu tvar ili bilo koje druge tiazinske boje
Indeed, driving can be affected due to confusional state, dizziness and possibly eye disturbances. 
Na sposobnost upravljanja vozilima mogu utjecati stanje konfuzije, omaglice i mogući poremećaji vida.
Advise patients to take protective measures against exposure to light, because photosensitivity may occur after administration of methylthioninium chloride. 
Savjetujte bolesnicima da poduzmu zaštitne mjere protiv izlaganja svjetlu, jer može doći do fotosenzitivnosti nakon primjene metiltioninijevog klorida.
The clinical consequences are considered likely to be minimal due to the transient and single dose use that normally occurs in the emergency setting. 
Smatra se da su kliničke posljedice vjerojatno minimalne s obzirom na prolaznu i jednokratnu upotrebu, obično u hitnim slučajevima.
They may appear green or blue - increased sensitivity of your skin to light (photosensitivity) 
Stolica može postati zelena ili plava - pojačana osjetljivost kože na svjetlost (fotosenzitivnost)
Pierrel S.p.A. s.s. Appia 7 bis, 46/48 - 81043 Capua, Italy 
Pierrel S.p.A. s.s. Appia 7 bis, 46/48 - 81043 Capua, Italija
Inject very slowly over a period of 5 minutes. 
Injicirati vrlo sporo u trajanju od 5 minuta.
The clinical consequences are however considered minimal since methylthioninium chloride Proveblue is used often only once and in an acute emergency setting. 
Međutim, smatra se da su kliničke posljedice minimalne s obzirom da se Methylthioninium chloride Proveblue često koristi samo jedanput i to u hitnim slučajevima.
Infants 3 months old or younger and newborn infants: 
Dojenčad u dobi od 3 mjeseca ili mlađa i novorođenčad:
If your blood disorder has been caused by aniline or dapsone, total cumulative dose should not exceed 4 mg/kg (see section 2). 
Ako je Vaš poremećaj krvi uzrokovan anilinom ili dapsonom, ukupna kumulativna doza ne bi smjela prijeći 4 mg/kg (vidjeti dio 2).
Like all medicines, Methylthioninium chloride Proveblue can cause side effects, although not everybody gets them. 
Kao i svi lijekovi, Methylthioninium chloride Proveblue može uzrokovati nuspojave iako se one neće javiti kod svakoga.
The efficacy of methylthioninium chloride for the treatment of methaemoglobinaemia in peadiatric population was demonstrated in two retrospective studies and one open randomised clinical trial. 
Djelotvornost metiltioninijeva klorida za liječenje methemoglobinemije u pedijatrijskoj populaciji je dokazana u dva retrospektivna ispitivanja i jednom otvorenom, randomiziranom kliničkom ispitivanju.
Your skin may turn blue - reduction in red blood cells which may turn your skin pale and make you breathless and weak, - jaundice (yellowing of the skin and eyes), this has only been reported in infants. 
Koža Vam može poplaviti - smanjenje broja crvenih krvnih stanica zbog čega Vaša koža može biti blijeda i što može učiniti da ostanete bez zraka i slabi - žutica (žutilo kože i očiju), prijavljena je samo kod dojenčadi.
Special care must be taken with Methylthioninium chloride Proveblue: - in newborns and infants 3 months old or younger, lower doses are recommended (see section 3 of this package leaflet). 
Posebna pozornost mora se obratiti na Methylthioninium chloride Proveblue: - kod novorođenčadi i dojenčadi od 3 mjeseca ili mlađe, preporučuju se niže doze (pogledajte dio
Pierrel S.p.A. s.s. Appia 7 bis, 46/48 IT-81043 Capua (CE) Italy 
Pierrel S.p.A. s.s. Appia 7 bis, 46/48 IT-81043 Capua (CE) Italija
However, if the intravenous use of methylthioninium chloride cannot be avoided, you should be administered the lowest possible dose and observed closely for up to 4 hours after administration. 
Ipak, ako se intravenska primjena metiltioninijeva klorida ne može izbjeći, treba Vam se primijeniti najmanja moguća doza i da budete pod pažljivim promatranjem do 4 sata nakon primjene.
If the intravenous use of methylthioninium chloride cannot be avoided in patients treated with serotonergic medicinal products, the lowest possible dose should be chosen and the patient observed closely for central nervous system (CNS) effects for up to 4 hours after administration (see sections 4.4 and 4.8). 
Ako intravensku primjenu metiltioninijeva klorida u bolesnika koji se liječe serotonergičkim lijekovima nije moguće izbjeći, potrebno je odabrati najnižu moguću dozu te je bolesnika potrebno pažljivo promatrati zbog učinaka na središnji živčani sustav (SŽS) u trajanju od 4 sata nakon primjene (vidjeti dijelove 4.4 i 4.8).
Serotonin Syndrome with concomitant use of serotonergic drugs (see section 4.4 and section 4.5). 
Vrlo često serotoninski sindrom prilikom istodobne uporabe serotonergičkih lijekova (vidjeti dio 4.4 i dio 4.5)
The adverse reactions listed in the table below occur in adults, children and adolescents (aged 0 to 17 years old) after intravenous administration. 
U sljedećoj su tablici prikazane nuspojave zabilježene u odraslih, djece i adolescenata (u dobi od 0-17 godina starosti) nakon intravenske primjene.
fluvoxamine, paroxetine, sertraline and zimelidine 
fluoksetin, fluvoksamin, paroksetin, sertralin i zimelidin.
• Common side effects (may affect up to 1 in 10 people): - stomach pain - chest pain - headache - anxiety - injection site pain - vomiting 
• Česte nuspojave (mogu se javiti u najviše 1 na 10 osoba): - bol u trbuhu - bol u prsištu - glavobolja - tjeskoba - bol na mjestu injiciranja - povraćanje
There are no adequate data from the use of methylthioninium chloride in pregnant women. 
Nema odgovarajućih podataka o primjeni metiltioninijeva klorida u trudnica.
Acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia. 
Akutno simptomatsko liječenje methemoglobinemije uzrokovane lijekovima i kemikalijama.
These include SSRIs (selective serotonin reuptake inhibitors), bupropion, buspirone, clomipramine, mirtazapine, and venlafaxine. 
Ti lijekovi uključuju SSRI-e (selektivni inhibitori ponovne pohrane serotonina), bupropion, buspiron, klomipramin, mirtazapin i venlafaksin.
• Selective serotonin reuptake inhibitors (SSRIs) such as citalopram, escitalopram, fluoxetine, 
• selektivne inhibitore ponovne pohrane serotonina (SSRI) kao što su citalopram, escitalopram,
The use of Methylthioninium chloride Proveblue during pregnancy is not recommended unless it is clearly necessary, for example in a life-threatening situation. 
Ne preporučuje se koristiti Methylthioninium chloride Proveblue tijekom trudnoće, osim ako je to neophodno potrebno, na primjer u situaciji opasnoj po život.
If any of the above applies to you, please consult your doctor. 
Ako se bilo što od gore navedenog odnosi na Vas, obratite se svom liječniku.
Methylthioninium chloride Proveblue must be injected very slowly over a period of 5 minutes to prevent high local concentrations of the compound from producing additional methaemoglobin. 
Methylthioninium chloride Proveblue mora se injicirati vrlo sporo tijekom perioda od 5 minuta da bi se spriječilo da visoke lokalne koncentracije lijeka prouzrokuju stvaranje dodatnog methemoglobina.
• mirtazapine 
• mirtazapin
• Monoamine oxidase inhibitors 
• inhibitore monoaminooksidaze
In the case of aniline- or dapsone-induced methaemaglobinaemia, the maximum recommended cumulative dose for the course of treatment is 4 mg/kg (see section 4.4). 
U slučaju methemoglobinemije uzrokovane anilinom ili dapsonom, maksimalna preporučena kumulativna doza tijekom cjelokupnog liječenja je 4 mg/kg (vidjeti dio 4.4).
Marketing Authorisation Holder Provepharm SAS 
Nositelj odobrenja za stavljanje lijeka u promet Provepharm SAS
In vivo, in low concentration, methylthioninium chloride speeds up the conversion of methaemoglobin to haemoglobin. 
In vivo, u niskoj koncentraciji, metiltioninijev klorid ubrzava pretvorbu methemoglobina u hemoglobin.
Avoid concomitant use of methylthioninium chloride with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (see section 4.5). 
Izbjegavajte istodobnu uporabu metiltioninijevog klorida sa selektivnim inhibitorima ponovne pohrane serotonina (SSRI), inhibitorima ponovne pohrane serotonina i noradrenalina (SNRI) te inhibitorima monoaminooksidaze (vidjeti dio 4.5).
Due to a lack of available data on whether methylthioninium chloride passes into human breast milk, breast-feeding should be discontinued for up to 8 days after treatment with this medicine. 
Zbog nepostojanja dostupnih podataka izlučuje li se metiltioninijev klorid u majčino mlijeko u ljudi, dojenje treba prekinuti do 8 dana nakon prestanka liječenja ovim lijekom.
For storage conditions of the diluted medicinal product, see section 6.3. 
Za uvjete čuvanja razrijeđenog lijeka, vidjeti dio 6.3.
Solution for injection 5 ampoules of 10 ml 
Otopina za injekciju 5 ampula od 10 ml
Some evidence of carcinogenic activity of methylthioniniul chloride has been shown in male mice and male rats. 
Pokazani su neki dokazi kancerogene aktivnosti metiltioninijeva klorida u muških miševa i muških štakora.
The maximum recommended cumulative dose for the course of treatment is 7 mg/kg and should not be exceeded, since Methylthioninium chloride administered above the maximum dose may cause methaemoglobinaemia in susceptible patients. 
Maksimalna preporučena kumulativna doza tijekom liječenja je 7 mg/kg i ne smije se prekoračiti jer metiltioninijev klorid primijenjen iznad maksimalne doze lijeka kod podložnih bolesnika može uzrokovati methemoglobinemiju.
The most commonly reported adverse reactions observed during clinical trials are dizziness, paraesthesia, dysgeusia, nausea, skin discoloration, chromaturia, sweating, injection site pain and pain in extremity. 
Najčešće prijavljene nuspojave zabilježene u kliničkim ispitivanjima su omaglica, parestezije, disgeuzija, mučnina, promjena boje kože, kromaturija, znojenje, bol na mjestu injiciranja i bol u ekstremitetu.
If symptoms of serotonin syndrome occur, discontinue use of methylthioninium chloride, and initiate supportive treatment. 
Ako dođe do pojave simptoma serotoninskog sindroma, prekinite uporabu metiltioninijevog klorida i započnite potporno liječenje.
Do not drive or use any tools or machines as methylthioninium chloride has moderate influence on the ability to drive and use machines. 
Nemojte upravljati vozilima i strojevima jer metiltioninijev klorid ima umjereni utjecaj na sposobnost upravljanja vozilima i strojevima.
Methylthioninium chloride (also called methylene blue) belongs to a group of medicines called antidotes. 
Metiltioninijev klorid (koji se još naziva i metilensko plavilo) pripada grupi lijekova koji se zovu protuotrovi.
Methylthioninium chloride may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs. 
Metiltioninijev klorid može izazvati ozbiljan ili fatalan serotoninski sindrom kada se koristi u kombinaciji sa serotonergičkim lijekovima.
Methylthioninium chloride Proveblue will be given to you or your child (0-17 years old) to treat problems with your blood resulting from exposure to some medicines or chemicals that can cause a disease called methaemoglobinaemia. 
Vi ili Vaše dijete (0-17 godina starosti) ćete dobiti Methylthioninium chloride Proveblue za liječenje problema s krvi koji proizlaze iz izlaganja nekim lijekovima ili kemikalijama koje mogu uzrokovati bolest koja se zove methemoglobinemija.
- if you suffer from hyperglycaemia or diabetes mellitus, as these conditions may be worsened by the glucose solution used for the dilution of the medicine - your urine and stools may turn a blue-green colour; and skin may possibly turn a blue colour when you are treated with Methylthioninium chloride Proveblue. 
- ako bolujete od hiperglikemije ili šećerne bolesti, jer otopina glukoze koja se koristi za razrjeđivanje lijeka može pogoršati ova stanja - Vaša mokraća i stolica mogu postati plavo-zelene boje i koža može poplaviti kada se liječite lijekom Methylthioninium chloride Proveblue.
The clinical consequences of increases plasma concentration of co-administered drugs which are sensitive CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A substrates cannot be ruled out. 
Nije moguće isključiti kliničke posljedice povećanja plazmatske koncentracije istodobno primijenjenih lijekova koji su osjetljivi supstrati CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 i 3A.
Your skin may turn blue blue or green urine numbness and tingling abnormal taste in mouth nausea 
Koža vam može poplaviti - plava ili zelena mokraća - utrnulost i trnci - abnormalan okus u ustima - mučnina
The administration of large intravenous doses (≥ 7 mg/kg) of Methylthioninium chloride Proveblue to individuals without methaemoglobinaemia induces nausea and vomiting, chest tightness, chest pain, tachycardia, apprehension, severe sweating, tremor, mydriasis, blue-green staining of the urine, blue staining of the skin and mucous membranes, abdominal pain, dizziness, paraesthesia, headache, confusion, hypertension, mild methaemoglobinaemia (up to 7%) and electrocardiogram changes (T wave flattening or inversion). 
Primjena velikih intravenskih doza (≥ 7 mg/kg) lijeka Methylthioninium chloride Proveblue u osoba bez methemoglobinemije izaziva mučninu i povraćanje, stezanje u prsištu, bol u prsištu, tahikardiju, strah, jako znojenje, tremor, midrijazu, plavo-zelenu obojenost mokraće, plavo obojenje kože i sluznica, bol u abdomenu, omaglicu, paresteziju, glavobolju, konfuziju, hipertenziju, blagu methemoglobinemiju (do 7%) i promjene na elektrokardiogramu (ravnanje ili inverziju T vala).
The excretion of methylthioninium chloride in milk has not been studied in animals. 
Izlučivanje metiltioninijeva klorida u mlijeko nije ispitivano na životinjama.
Methylthioninium chloride was mutagenic in gene mutation assays in bacteria and mouse lymphoma cells but not in vivo mouse micronucleus assay when administered intravenously at 62 mg/kg. 
Metiltioninijev klorid je bio mutagen u testovima mutacije gena u bakterija i stanicama limfoma miševa, ali ne i na in vivo mikronukleusnom testu miševa kod intravenske primjene 62 mg/kg.
• clomipramine 
• klomipramin
52, Rue Marcel et Jacques Gaucher 94120 Fontenay-sous-Bois France 
52, Rue Marcel et Jacques Gaucher 94120 Fontenay-sous-Bois Francuska
Too limited data are available to support a continuous infusion dose recommendation. 
Za preporuku doze za kontinuiranu infuziju ne postoji dovoljno dostupnih podataka.
It imparts a blue-green colour to urine, faeces and a blue colour to skin which may hinder a diagnosis of cyanosis. 
Uzrokuje plavo-zelenu boju mokraće, stolice te plavu boju kože zbog koje može onemogućiti dijagnosticiranje cijanoze.
Based on kinetic data, breast-feeding should be discontinued for up to 8 days after treatment with Methylthioninium chloride Proveblue. 
Na temelju kinetičkih podataka, dojenje treba prekinuti do 8 dana nakon prestanka liječenja lijekom Methylthioninium chloride Proveblue.
5 ampoules of 2 ml 20 ampoules of 2 ml 10 mg/2 ml 
5 ampula od 2 ml 20 ampula od 2 ml 10 mg/2 ml
Extreme caution should be exercised when administering to newborns and infants below the age of 3 months due to lower concentrations of NADPH-methaemoglobin reductase necessary for reducing methaemoglobin to haemoglobin, making these infants more susceptible to methaemoglobinaemia produced by high doses of methylthioninium chloride. 
Nužan je izraziti oprez pri primjeni u novorođenčadi i dojenčadi mlađe od 3 mjeseca zbog nižih koncentracija NADPH-methemoglobin reduktaze potrebne za redukciju methemoglobina u hemoglobin, zbog čega je dojenčad podložnija methemoglobinemiji uzrokovanoj visokim dozama metiltioninijeva klorida.
You should not be given this medicine after the expiry date which is printed on the carton and the ampoule labels after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnicama ampule iza „Rok valjanosti“ ili „EXP“.
Methylthioninium chloride should be avoided in patients receiving medicinal products that enhance serotonergic transmission because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome. 
Metiltioninijev klorid trebaju izbjegavati bolesnici koji primaju lijekove koji pojačavaju serotonergički prijenos zbog potencijalnih ozbiljnih reakcija SŽS-a, uključujući potencijalno fatalni serotoninski sindrom.
Methylthioninium chloride Proveblue can exacerbate dapsone-induced haemolytic anemia because of the formation of the dapsone reactive metabolite hydroxylamine which oxidises haemoglobin. 
Methylthioninium chloride Proveblue može pogoršati hemolitičku anemiju izazvanu dapsonom zbog stvaranja reaktivnog metabolita dapsona hidroksilamina, koji oksidira hemoglobin.
Preparation for intravenous administration 
Priprema za intravensku primjenu
Patients with hyperglycaemia or diabetes mellitus 
Bolesnici s hiperglikemijom ili šećernom bolesti
What Methylthioninium chloride Proveblue is and what it is used for What you need to know before you are given Methylthioninium chloride Proveblue How Methylthioninium chloride Proveblue is given Possible side effects 
Što je Methylthioninium chloride Proveblue i za što se koristi Što morate znati prije nego primite Methylthioninium chloride Proveblue Kako primjenjivati Methylthioninium chloride Proveblue Moguće nuspojave
Methylthioninium chloride is an in vitro inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5. 
Metiltioninijev klorid je in vitro inhibitor CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 i 3A4/5.
How to store Methylthioninium chloride Proveblue Contents of the pack and other information 
Kako čuvati Methylthioninium chloride Proveblue Sadržaj pakiranja i druge informacije
It must be injected very slowly over a period of 5 minutes. 
Lijek se mora injicirati vrlo sporo tijekom perioda od 5 minuta.
• Patients with methaemoglobinaemia due to chlorate poisoning 
• Bolesnici s methemoglobinemijom zbog trovanja kloratom
Methylthioninium chloride is a potent inhibitor of the transporters OCT2, MATE1 and MATE2-K. 
Metiltioninijev klorid snažan je inhibitor transportera OCT2, MATE1 i MATE2-K.
The administration of methylthioninium chloride Proveblue has the potential to transiently increase or decrease the clearance of drugs that are primarily metabolized by these enzymes. 
Primjena lijeka Methylthioninium chloride Proveblue može prolazno povećati ili smanjiti klirens lijekova koji se prvenstveno metaboliziraju ovim enzimima.
Adverse reactions, seen at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were moderate regenerative anaemia associated with increased mean platelet count and fibrinogen levels, a minimal increase in mean total bilirubin blood values and an increased incidence of moderate urine bilirubin levels. 
Nuspojave, viđene na razinama izloženosti sličnim kliničkim razinama izloženosti i uz mogući značaj za kliničku primjenu su bile umjerena regenerativna anemija povezana s povišenjem srednje vrijednosti broja trombocita i razina fibrinogena, malo povišenje srednjih vrijenosti razina bilirubina u krvi i povećanje incidencije umjerenih razina bilirubina u mokraći.
Cenexi 52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, France 
Cenexi 52, Rue Marcel et Jacques Gaucher, 94120 Fontenay-sous-Bois, Francuska
You must not be given Methylthioninium chloride Proveblue: - if you are allergic to methylthioninium chloride or other thiazine dyes - if your body does not produce enough of the enzyme G6PD (glucose-6-phosphate dehydrogenase) - if your body does not produce enough of the enzyme NADPH (nicotinamide adenine dinucleotide phosphate) reductase - if your blood disorder has been caused by nitrite during treatment of cyanide poisoning - if your blood disorder has been caused by chlorate poisoning. 
Ne smijete primiti Methylthioninium chloride Proveblue: - ako ste alergični na metiltioninijev klorid ili druge tiazinske boje - ako Vaše tijelo ne stvara dovoljno enzima G6PD (glukoza-6-fosfat dehidrogenaza) - ako Vaše tijelo ne stvara dovoljno enzima NADPH (nikotinamid adenin dinukleotid fosfat)
Methylthioninium chloride Proveblue is not an in vitro substrate for BCRP or OCT2 and is not an in vitro inhibitor of BCRP, OAT1 or OAT3. 
Methylthioninium chloride Proveblue nije in vitro supstrat za BCRP ili OCT2 i nije in vitro inhibitor BCRP, OAT1 ili OAT3.
Individuals without methaemoglobinaemia 
Osobe bez methemoglobinemije
What Methylthioninium chloride Proveblue is and what it is used for 
Što je Methylthioninium chloride Proveblue i za što se koristi
Caution should be exercised in the course of treatment with methylthioninium chloride as this may exacerbate Heinz body formation and haemolytic anaemia. 
Nužan je oprez tijekom liječenja metiltioninijevim kloridom jer može pogoršati formiranje Heinzovih tijela i hemolitičke anemije.
When used in combination with these medicines methylthioninium chloride may cause serotonin syndrome, which can be potentially life-threatening. 
Kada se koristi u kombinaciji s tim lijekovima, metiltioninijev klorid može izazvati serotoninski sindrom koji može biti opasan po život.
Type I glass ampoules. 
Ampule od stakla tipa I.
In cases of suspected methaemoglobinaemia, it is advisable to check the oxygen saturation by cooximetry when available since pulse oximetry may provide a false estimation of oxygen saturation during administration of methylthioninium chloride. 
U slučajevima sumnje na methemoglobinemiju, savjetuje se provjeriti zasićenost kisikom putem kooksimetrije, ako je moguće, jer tijekom primjene metiltioninijeva klorida, pulsna oksimetrija može dati pogrešnu procjenu zasićenosti kisikom.
• Patients with nitrite-induced methaemoglobinaemia during treatment of cyanide poisoning 
• Bolesnici s methemoglobinemijom uzrokovanom nitritom tijekom liječenja trovanja cijanidom
What Methylthioninium chloride Proveblue looks like and contents of the pack Methylthioninium chloride Proveblue is a clear dark blue solution for injection (injection) and is supplied in clear glass ampoules. 
Kako Methylthioninium chloride Proveblue izgleda i sadržaj pakiranja Methylthioninium chloride Proveblue je bistra tamnoplava otopina za injekciju (injekcija) i isporučuje se u prozirnim staklenim ampulama.
In patients with aniline-induced methaemoglobinaemia, repeated doses of methylthioninium chloride may be required. 
U bolesnika s methemoglobinemijom izazvanom anilinom mogu biti potrebne ponovljene doze metiltioninijeva klorida.
• buspirone 
• buspiron
Anaesthesiologists should be vigilant for methaemoglobinaemia in patients receiving dapsone therapy and for BIS (Bispectral Index) interference with Methylthioninium chloride Proveblue administration. 
Anesteziolozi moraju obratiti posebnu pozornost na methemoglobinemiju u bolesnika koji primaju terapiju dapsona i interferenciju BIS-a (bispektralni indeks) tijekom primjene Methylthioninium chloride Proveblue.